References
- Sasse F, Steinmetz H, Schupp T, Petersen F, Memmert K, Hofmann H, et al. 2002. Argyrins, immunosuppressive cyclic peptides from myxobacteria. I. Production, isolation, physico-chemical and biological properties. J. Antibiot. 55: 543-551. https://doi.org/10.7164/antibiotics.55.543
- Vollbrecht L, Steinmetz H, Hofle G, Oberer L, Rihs G, Bovermann G, et al. 2002. Argyrins, immunosuppressive cyclic peptides from myxobacteria. II. Structure elucidation and stereochemistry. J. Antibiot. 55: 715-721. https://doi.org/10.7164/antibiotics.55.715
- Ferrari P, Vekey K, Galimberti M, Gallo GG, Selva E, Zerilli LF. 1996. Antibiotics A21459 A and B, new inhibitors of bacterial protein synthesis. II. Structure elucidation. J. Antibiot. 49: 150-154. https://doi.org/10.7164/antibiotics.49.150
- Selva E, Gastaldo L, Saddler GS, Toppo G, Ferrari P, Carniti G, et al. 1996. Antibiotics A21459 A and B, new inhibitors of bacterial protein synthesis. I. Taxonomy, isolation and characterization. J. Antibiot 49: 145-149. https://doi.org/10.7164/antibiotics.49.145
- Pogorevc D, Tang Y, Hoffmann M, Zipf G, Bernauer HS, Popoff A, et al. 2019. Biosynthesis and heterologous production of argyrins. ACS Synth. Biol. 8: 1121-1133. https://doi.org/10.1021/acssynbio.9b00023
- Nyfeler B, Hoepfner D, Palestrant D, Kirby CA, Whitehead L, Yu R, et al. 2012. Identification of elongation factor G as the conserved cellular target of argyrin B. PLoS One 7: e42657. https://doi.org/10.1371/journal.pone.0042657
- Ley SV, Priour A, Heusser C. 2002. Total synthesis of the cyclic heptapeptide Argyrin B: a new potent inhibitor of T-cell independent antibody formation. Org. Lett. 4: 711-714. https://doi.org/10.1021/ol017184m
- Nickeleit I, Zender S, Sasse F, Geffers R, Brandes G, Sorensen I, et al. 2008. Argyrin A reveals a critical role for the tumor suppressor protein p27kip1 in mediating antitumor activities in response to proteasome inhibition. Cancer Cell. 14: 23-35. https://doi.org/10.1016/j.ccr.2008.05.016
- Bulow L, Nickeleit I, Girbig AK, Brodmann T, Rentsch A, Eggert U, et al. 2010. Synthesis and biological characterization of argyrin F. ChemMedChem 5: 832-836. https://doi.org/10.1002/cmdc.201000080
- Stauch B, Simon B, Basile T, Schneider G, Malek NP, Kalesse M, et al. 2010. Elucidation of the structure and intermolecular interactions of a reversible cyclic-peptide inhibitor of the proteasome by NMR spectroscopy and molecular modeling. Angew. Chem. Int. Ed. Engl. 49: 3934-3938. https://doi.org/10.1002/anie.201000140
- Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, et al. 1994. Cloning of p27kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59-66. https://doi.org/10.1016/0092-8674(94)90572-x
- Allardyce DJ, Bell CM, Loizidou EZ. 2019. Argyrin B, a non-competitive inhibitor of the human immunoproteasome exhibiting preference for β1i. Chem. Biol. Drug Des. 94: 1556-1567. https://doi.org/10.1111/cbdd.13539
- Chen X, Bui KC, Barat S, Nguyen MLT, Bozko P, Sipos B, et al. 2017. Therapeutic effects of Argyrin F in pancreatic adenocarcinoma. Cancer Lett. 399: 20-28. https://doi.org/10.1016/j.canlet.2017.04.003
- Hyun H, Choi J, Kang D, Kim Y, Lee P, Chung GJY, et al. 2021. Screening of myxobacteria carrying tubulysin biosynthetic genes. Microbiol. Biotechnol. Lett. 49: 32-38. https://doi.org/10.48022/mbl.2010.10001
- Shin H, Youn J, An D, Cho K. 2013. Production of antimicrobial substances by strains of myxobacteria Corallococcus and Myxococcus. Korean J. Microbiol. Biotechnol. 41: 44-51. https://doi.org/10.4014/kjmb.1210.10011
- Zimbro MJ, Power DA, Miller SM, Wilson GE, Johnson JA (eds.). 2009. Difco and BBL manual: Manual of microbiological culture media. 2nd ed. Becton Dickinson and Co., Sparks, MD.
- Cho K, Zusman DR. 1999. AsgD, a new two-component regulator required for A-signalling and nutrient sensing during early development of Myxococcus xanthus. Mol. Microbiol. 34: 268-281. https://doi.org/10.1046/j.1365-2958.1999.01594.x
- Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, N.Y., USA.
- Blin K, Shaw S, Steinke K, Villebro R, Ziemert N, et al. 2019. antiSMASH 5.0: updates to the secondary metabolite genome mining pipeline. Nucleic Acids Res. 47: W81-W87. https://doi.org/10.1093/nar/gkz310
- Johnson M, Zaretskaya I, Raytselis Y, Mereshuk Y, McGinnis S, Madden TL. 2008. NCBI BLAST: a better web interface. Nucleic Acids Res. 36: W5-W9. https://doi.org/10.1093/nar/gkn201
- Shimkets LJ. 1986. Correlation of energy-dependent cell cohesion with social motility in Myxococcus xanthus. J. Bacteriol. 166: 837-841. https://doi.org/10.1128/jb.166.3.837-841.1986
- Gerth K, Pradella S, Perlova O, Beyer S, Muller R. 2003. Myxobacteria: proficient producers of novel natural products with various biological activities - past and future biotechnological aspects with the focus on the genus Sorangium. J. Biotechnol. 106: 233-253. https://doi.org/10.1016/j.jbiotec.2003.07.015
- Schaberle TF, Lohr F, Schmitz A, Konig GM. 2014. Antibiotics from myxobacteria. Nat. Prod. Rep. 31: 953-972. https://doi.org/10.1039/c4np00011k
- Hyun H, Cho K. 2018. Secondary metabolites of myxobacteria. Korean J. Microbiol. 54: 175-187. https://doi.org/10.7845/KJM.2018.8042
- Choi J, Park T, Kang D, Lee J, Kim Y, Lee P, et al. 2021. Analysis of tubulysin biosynthetic genes in Archangium gephyra. Microbiol. Biotechnol. Lett. 49: 458-465.